News & Updates

In patients with type 2 diabetes (T2D), moderate-intensity statin in combination with ezetimibe results in greater reductions in low-density lipoprotein cholesterol (LDL-C) and better prevention of adverse outcomes when compared with high-intensity statin monotherapy, suggests a study.

Off-label pulmonary arterial hypertension (PAH)-targeted drugs may increase long-term survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH), as shown in a study.

A recent study has found more potential drug‒drug interactions in breast cancer patients receiving doxorubicin and cyclophosphamide regimen in the Drugs.com database than in the Lexicomp and Micromedex databases.